Search

Your search keyword '"Hernández-García, M T"' showing total 3 results
Start Over Author "Hernández-García, M T" Publisher elsevier espana
3 results on '"Hernández-García, M T"'

1. Relevance of early diagnosis in polycythemia vera and essential thrombocythemia: A single center's experience.

Author

Lakhwani S, Pardina-Echevarría M, Arcas-Vega R, Díaz-Sánchez OR, Hernández-García MT, and Raya JM

Subjects
Early Diagnosis, Humans, Polycythemia Vera diagnosis, Polycythemia Vera therapy, Thrombocythemia, Essential diagnosis, Thrombocythemia, Essential therapy, Thrombocytosis diagnosis, Thrombocytosis etiology, Thrombocytosis therapy, Thrombosis diagnosis, Thrombosis etiology
Abstract

Objectives: This work aims to describe the proportion of patients with polycythemia vera (PV) or essential thrombocythemia (ET) and thrombosis prior to the diagnosis who had erythrocytosis or thrombocytosis prior to the thrombosis., Patients and Methods: This is a retrospective review of 63 patients with PV and 130 with ET., Results: In regard to PV, we found prior erythrocytosis in 7 (11.1%) of the 17 cases (27%) with thrombosis prior to diagnosis. In ET, we found prior thrombocytosis in 10 (7.7%) of the 25 cases (19.2%) with thrombosis prior to diagnosis. The median time between the laboratory finding and thrombosis was 8.2 months and 11.8 months for PV and TE, respectively. In both entities, patients with thrombosis prior to diagnosis had significantly lower survival., Conclusion: A significant proportion of patients with thrombosis prior to the diagnosis of PV and ET present with erythrocytosis or thrombocytosis prior to the episode of thrombosis. This could allow for anticipating diagnosis and treatment., (Copyright © 2021 Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI). All rights reserved.)

Published
2022
Full Text
View/download PDF

2. [The beneficial effect of 1,25-dihydroxycholecalciferol on the excess of blasts and the myelofibrosis in 2 cases of chronic myeloproliferative syndrome].

Author

Raya Sánchez JM, Hernández Nieto L, Brito Barroso ML, and Hernández García MT

Subjects
Anemia, Refractory, with Excess of Blasts pathology, Biopsy, Bone Marrow drug effects, Bone Marrow pathology, Chronic Disease, Female, Humans, Male, Middle Aged, Polycythemia Vera drug therapy, Polycythemia Vera pathology, Primary Myelofibrosis pathology, Remission Induction, Syndrome, Anemia, Refractory, with Excess of Blasts drug therapy, Calcitriol therapeutic use, Primary Myelofibrosis drug therapy
Abstract

The active metabolite of vitamin D3 1.25 dehydroxycholecalciferol (1.25DHCC) is a potent inducer of monocytic differentiation of the myeloid blasts "in vitro". Likewise the inhibiting role of vitamin D3 on bone marrow fibrosis by, among others, a stimulating effect of macrophagic activity is known. However, these actions have seldom been clinically demonstrated. Two cases of chronic myeloproliferative syndromes in which treatment with 1.25DHCC was effective are presented. In the first case, one patient with polycythemia vera with myelofibrosis and focal blastosis in the bone marrow achieved disappearance of the excess of blasts and a reduction in the fibrosis (grade III to grade I) upon treatment. In the second case, idiopathic myelofibrosis, also with focal blastosis in the bone marrow biopsy, there was no regression of the fibrosis but the blastosis did disappear. It was concluded that 1.25DHCC may constitute an interesting treatment in this group of diseases through the following two mechanisms: limitation of the fibrosis and delay of blast transformation.

Published
1994

Catalog

Books, media, physical & digital resources
See catalog results